Compare FTH & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTH | IRWD |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.7M | 687.4M |
| IPO Year | 2021 | 2009 |
| Metric | FTH | IRWD |
|---|---|---|
| Price | $19.61 | $3.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $56.14 | $6.10 |
| AVG Volume (30 Days) | 331.0K | ★ 1.8M |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $59.19 |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | ★ N/A | $6.35 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $17.50 | $1.47 |
| 52 Week High | $42.14 | $5.78 |
| Indicator | FTH | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 29.10 | 38.25 |
| Support Level | N/A | $3.04 |
| Resistance Level | $36.63 | $3.96 |
| Average True Range (ATR) | 2.32 | 0.18 |
| MACD | -0.72 | -0.03 |
| Stochastic Oscillator | 11.64 | 6.62 |
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.